Amgen agrees to develop biosimilars for Chinese market
Increasing its global footprint in the biosimilars market, Amgen announced Sept. 26 that it had formed an exclusive co-development agreement with Chinese drug manufacturer Simcere Pharmaceutical Group. The agreement aims to bring four oncology and inflammation biosimilars in Amgen’s portfolio to commercialization in China. The Thousand Oaks-based biotechnology company will produce and submit approval applications Read More →
Read More →Amgen partnering with Japanese company to develop biosimilars
Thousand Oaks-based biotech giant Amgen said July 13 it will partner with a Japanese company to develop and commercialize biosimilars in Japan. Under the partnership, Amgen will develop and manufacture biosimilars while Daiichi Sankyo will obtain marketing approval, distribution and commercialization rights in Japan for the products. The deal also includes several late-stage development drugs. Read More →
Read More →Amgen seeks European OK of biosimilar drug, partners with Merck on studies
Amgen announced two developments Dec. 4 that should help the Thousand Oaks-based biotech giant compete. Amgen said it is seeking approval from the European Medicines Agency for ABP 501, a biosimilar drug similar to Humira. Amgen also announced a partnership with New Jersey-based pharmaceutical Merck to partner in a non-Hodgkins lymphoma study using drugs from Read More →
Read More →
Amgen bipolar about biosimilars
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen’s portfolio threatened as FDA paves path for lower-cost drugs
Zarxio, the first biopharmaceutical copycat approved in the U.S., will pave the way for lower-cost alternatives to existing treatments.
Read More →Gov. Brown vetoes Amgen-backed anti-biosimilars bill
Gov. Jerry Brown vetoed a bill supported by Thousand Oaks-based Amgen and other biotechnology companies that would have made it more difficult for pharmacists to dispense so-called biosimilars, the biotech industry’s analogue to generic pharmaceuticals.
Senate Bill 598, approved by both houses of the legislature, looked mostly like a procedural change to state’s pharmacy laws. If it passed, the bill would have allowed pharmacists to fill prescriptions with biosimilars that the U.S. Food and Drug Administration deems “interchangeable” with brand-name counterparts.
Read More →
Sponsored content:
2015-2016 Giving Guide
